Zinc-Thymulin: Evidence, Mechanism, Dosing & Legal Status

Zinc-thymulin is the active, zinc-bound form of thymulin (formerly Facteur Thymique Serique, FTS), a thymic nonapeptide hormone discovered in 1977 whose entire biological activity depends on zinc.3 In the consumer market it is sold as a topical hair-growth peptide; in the older immunology literature it is a sensitive marker of zinc status. This monograph separates the well-grounded biology from the single-study hair claim and the vendor hype.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Zinc-thymulin is an unapproved investigational peptide sold as a research chemical not for human use. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is zinc-thymulin and how does it work?

Thymulin is a nonapeptide with the sequence pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (molecular weight about 858-859 Da), discovered by Bach and Dardenne at the Institut Necker in Paris and produced selectively by thymic epithelial cells.3 Its identity was confirmed by mass spectrometry in the clinical paper (MW 858.85).1

The core mechanism is that zinc is the switch. The peptide alone — apo-thymulin, or FTS — is biologically inactive. Activity requires zinc bound in a one-to-one ratio, which induces a specific three-dimensional conformation (confirmed by NMR) and creates a new antibody-defined epitope; only this zinc-thymulin metallopeptide is active.3 Thymic epithelial cells contain zinc and metallothionein, implying the hormone is secreted in its active, zinc-bound form.3 This zinc-dependence is the unifying theme across both the immune and hair indications.

On the immune side, zinc-thymulin induces T-cell differentiation and modulates T-cell subsets, NK activity, and lymphokine production; in zinc-deficient humans, low thymulin activity reflects reduced zinc saturation of the peptide rather than primary thymic failure, and is correctable by zinc.4 On the scalp, human hair follicles endogenously express thymulin, and in human hair-follicle organ culture thymulin prolongs anagen and stimulates hair-shaft elongation — the opposite direction to thymosin beta-4 — while also increasing follicular melanin, a mechanistic basis for the re-pigmentation later seen clinically.2 Rigorous human pharmacokinetics for synthesized topical zinc-thymulin (plasma half-life, scalp absorption, systemic exposure) are not established; any half-life figures in vendor dosing guides are unverified.1

What is the evidence by indication?

The evidence splits cleanly into a single hair trial, a well-grounded zinc-biomarker story, and preclinical-only claims for everything else. The table summarizes where each indication actually stands.

The hair evidence is the most marketed and the most over-extrapolated. The lone clinical study enrolled 18 consecutive adults (17 male, 1 female), age 35-90, with treatment durations of four to ten months, using a 0.0005% zinc-thymulin spray twice daily.1 The whole-group global visual-analog change was not significant (P=0.07); significance appeared only in the 11 subjects who completed at least six months (P=0.045). Hair-count analysis showed significantly less absent hair after treatment (P=0.008) and a rise in intermediate hairs, with reported average increases of about 32% vellus and 23% intermediate hairs at six months — but no robust net terminal-hair gain.1 The supporting mechanism comes from human hair-follicle organ culture showing thymulin prolongs anagen.2 The verdict for hair: promising and biologically plausible, but graded B and heavily caveated by the absence of a placebo arm, subgroup-dependent significance, a small and heterogeneous sample, a single investigator and sponsor, and a low-impact journal.

The immune and zinc-status evidence is, paradoxically, the more solid science. Prasad and colleagues studied human models of mild zinc deficiency and showed that mild zinc deficiency lowered serum thymulin activity and that zinc repletion — both in vivo and in vitro — restored it, alongside normalization of the T4+/T8+ ratio and interleukin-2 activity.4 This establishes thymulin as a sensitive human biomarker of zinc status. Crucially, it does not demonstrate that administering exogenous zinc-thymulin treats any disease; claims of reduced infections or improved immune counts trace to small, old, largely unreplicated reports and are best graded C-to-D. You can review the original mechanistic paper at the NIH's open-access archive: PMC442670 on PubMed Central.

What doses appear in the literature?

Reported strictly as information, not a protocol. The only published human regimen is topical: a 0.0005% zinc-thymulin water-based spray (pH 5.4, with benzoic-acid and sorbate preservatives), one to two milliliters sprayed and rubbed into the scalp twice daily, with bottles re-supplied fresh every six to eight weeks.1 A meaningful response signal appeared only after at least six months of continuous use.1 In the trial, zinc was attached to synthesized thymulin via zinc oxide in a 1:3 weight ratio and lyophilized, then dissolved in buffered, preserved water.1 Compounding pharmacies commonly pair topical zinc-thymulin with the copper peptide GHK-Cu in hair formulas, but that combination has no published human efficacy trial and is marketing- or clinical-experience-based only. Vendor injectable thymulin dosing guides for the immune indication exist but are not supported by controlled human dosing trials and are omitted here as unverified. The best-evidenced lever relevant to thymulin biology is correcting zinc deficiency, since zinc repletion restores endogenous thymulin activity in zinc-deficient people — a nutritional question for a clinician, not a peptide protocol.4

How safe is zinc-thymulin?

Over more than 3,300 total treatment-days, the topical trial reported no systemic effects and no local irritation, redness, or hair deterioration attributable to the active.1 The single adverse event was one transient hour of forehead redness in one subject, which the investigator attributed to the citric-acid buffer acting on sun-exposed, abraded skin — a vehicle effect, not the peptide — and the subject continued without recurrence.1 No drug interactions were seen with concomitant minoxidil or finasteride. The important caveat is that no-adverse-events comes from a single, small, short-to-medium-term, uncontrolled study with no toxicology dossier, so it cannot exclude rare or long-term harms. Theoretically, an immunomodulatory T-cell-differentiating peptide could alter immune tone systemically, though relevance to a low-concentration topical with negligible measured systemic exposure is unknown, and long-term oncologic safety is simply unstudied.1 Pregnancy and lactation have no data and should be avoided, as should use by anyone with known zinc or peptide hypersensitivity. Because it is an unapproved research chemical, it is appropriately avoided outside a research or clinical-oversight setting.

What is the FDA and WADA status in 2026?

Zinc-thymulin and thymulin are not FDA-approved for any human indication, have no USP monograph, and are not components of an approved drug.6 They are sold by chemical suppliers labeled research chemical, not for human use. On compounding, FDA materials surface actions on the related thymic peptide thymosin alpha-1 and the September 2024 removal of several peptides from interim Category 2.7 Under the interim policy effective January 7, 2025, the FDA stopped sorting newly nominated bulk substances into interim categories, so substances not already on the final 503A list generally may not be compounded pending full review.8 No primary FDA record places thymulin specifically on the final 503A bulks list, so its compounding standing in 2026 is, at best, unsettled and likely impermissible as a bulk substance absent that listing.6

For athletes, the picture is less settled than for banned peptides like BPC-157. Thymulin and zinc-thymulin are not specifically named on the 2026 WADA Prohibited List — the 2026 additions to the relevant category were BAM15 and a flavone, not thymulin.9 However, peptide hormones and growth-and-immune modulators are scrutinized categories, and un-named is not the same as guaranteed-permitted; athletes under WADA, USADA, or NCAA rules should verify current status and exercise caution before competition.10 It is not a DEA-controlled substance.

Bottom line. Zinc-thymulin pairs a genuinely solid zinc-status immunobiology story with a single, uncontrolled human hair trial and a great deal of vendor hype. From a functional-medicine standpoint the most defensible, best-evidenced lever is correcting the upstream zinc deficiency that suppresses endogenous thymulin — not the synthesized topical peptide, which remains a reasonable, low-risk experimental adjunct in principle but is honestly investigational, single-study evidence, not an established therapy. Regulatory facts here are current as of June 2026 and should be re-verified against the live FDA 503A bulks list and the WADA list before relying on them.